Osteoporosis - A risk factor for cardiovascular disease?

Nature Reviews Rheumatology

Volumn 8, Issue 10, 2012, Pages 587-598

  Lampropoulos, Christos E ^a   Papaioannou, Ioanna ^b   D'Cruz, David P ^c  

^a General Hospital of Nafplio   (Greece)

^b Ministry of Health   (Greece)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CATHEPSIN K; LIPID; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHATE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; VITAMIN D; VITAMIN K GROUP; WNT PROTEIN;

BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DYSLIPIDEMIA; HISTOPATHOLOGY; HUMAN; MOLECULAR MECHANICS; NONHUMAN; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOPOROSIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; OSTEOPOROSIS; VASCULAR CALCIFICATION;

EID: 84867068673     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.120     Document Type: Review

References (148)

1. Reginster, J.Y.& Burlet, N.Osteoporosis: A still increasing prevalence.Bone 38 (Suppl.), S4-S9 (2006).(Pubitemid 43190767)
2. Sweet, M.G., Sweet, J.M., Jeremiah, M.P.& Galazka, S.S.Diagnosis and treatment of osteoporosis.Am.Fam.Physician 79, 193-200 (2009).
3. Sambrook, P.& Cooper, C.Osteoporosis.Lancet 367, 2010-2018 (2006).(Pubitemid 43867702)
4. Cummings, S.R.& Melton, L.J.Epidemiology and outcomes of osteoporotic fractures.Lancet 359, 1761-1767 (2002).
5. Greenland, P.et al.ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: A report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography).Circulation 115, 402-426 (2007).(Pubitemid 46148515)
6. Demer, L.L.& Tintut, Y.Vascular calcification: pathobiology of a multifaceted disease.Circulation 117, 2938-2948 (2008).(Pubitemid 351787058)
7. Wilson, P.W.et al.Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality.Circulation 103, 1529-1534 (2001).(Pubitemid 32226260)
8. Tan, S.D.et al.Osteocytes subjected to fluid flow inhibit osteoclast formation and bone resorption.Bone 41, 745-751 (2007).(Pubitemid 47576844)
9. Eriksen, E.F.Cellular mechanisms of bone remodeling.Rev.Endocr.Metab. Disord.11, 219-227 (2010).
10. Radi, Z.A., Guzman, R.E.& Bell, R.R.Increased connective tissue extracellular matrix in the op/op model of osteopetrosis.Pathobiology 76, 199-203 (2008).
11. Teitelbaum, S.L.Osteoclasts: what do they do and how do they do it? Am.J.Pathol.170, 427-435 (2007).(Pubitemid 47339379)
12. Feskanich, D.et al.Vitamin K intake and hip fractures in women: A prospective study.Am.J.Clin.Nutr.69, 74-79 (1999).(Pubitemid 29031254)
13. Szulc, P., Chapuy, M.C., Meunier, P.J.& Delmas, P.D.Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women.J.Clin.Invest.91, 1769-1774 (1993).(Pubitemid 23127383)
14. Luukinen, H.et al.Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin.J.Bone Miner.Res.15, 2473-2478 (2000).
15. Knapen, M.H., Nieuwenhuijzen Kruseman, A.C., Wouters, R.S.& Vermeer, C.Correlation of serum osteocalcin fractions with bone mineral density in women during the first 10 years after menopause.Calcif.Tissue Int.63, 375-379 (1998).(Pubitemid 28476325)
16. London, G.M.et al.Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality.Nephrol.Dial. Transplant.18, 1731-1740 (2003).(Pubitemid 37098542)
17. Guzman, R.J.Clinical, cellular and molecular aspects of arterial calcification.J.Vasc.Surg.45 (Suppl.A), A57-A63 (2007).
18. Smith, E.R.et al.Elastin degradation is associated with progressive aortic stiffening and all-cause mortality in predialysis chronic kidney disease.Hypertension 59, 973-978 (2012).
19. Willens, H.J.et al.The relation between mitral annular calcification and mortality in patients undergoing diagnostic coronary angiography. Echocardiography 23, 717-722 (2006).(Pubitemid 44450524)
20. Ross, E.A.Evolution of treatment strategies for calciphylaxis.Am.J. Nephrol.34, 460-467 (2011).
21. Libby, P.& Theroux P.Pathophysiology of coronary artery disease.Circulation 111, 3481-3488 (2005).(Pubitemid 40923403)
22. Shao, J.S., Cheng, S.L., Sadhu, J.& Towler, D.A.Inflammation and the osteogenic regulation of vascular calcification: A review & perspective.Hypertension 55, 579-592 (2010).
23. Nakano-Kurimoto, R.et al.Replicative senescence of vascular smooth muscle cells enhances the calcification through initiating the osteoblastic transition.Am.J.Physiol.Heart Circ.Physiol.297, 1673-1684 (2009).
24. Vattikuti, R.& Towler, D.A.Osteogenic regulation of vascular calcification: An early perspective.Am.J.Physiol.Endocrinol.Metab.286, 686-696 (2004).
25. Rajamannan, N.M.et al.Human aortic valve calcification is associated with an osteoblast phenotype.Circulation 107, 2181-2184 (2003).(Pubitemid 36547209)
26. Osman, L., Yacoub, M.H., Latif, N., Amrani, M.& Chester, A.H.Role of human valve interstitial cells in valve calcification and their response to atorvastatin.Circulation 114, 1547-1552 (2006).
27. Farrington-Rock, C.et al.Chondrogenic and adipogenic potential of microvascular pericytes.Circulation 110, 2226-2232 (2004).(Pubitemid 39372506)
28. Rennenberg, R.J.et al.Calcium scores and matrix Gla protein levels: Association with vitamin K status.Eur.J.Clin.Invest.40, 344-349 (2010).
29. Gazzerro, E., Rydziel, S.& Canalis, E.Skeletal bone morphogenetic proteins suppress the expression of collagenase-3 by rat osteoblasts. Endocrinology 140, 562-567 (1999).(Pubitemid 29058185)
30. Boden, S.D.et al.Glucocorticoid-induced differentiation of fetal rat calvarial osteoblasts is mediated by bone morphogenetic protein-6.Endocrinology 138, 2820-2828 (1997).(Pubitemid 27258512)
31. Csiszar, A.et al.Bone morphogenetic protein-2 induces proinflammatory endothelial phenotype.Am.J.Pathol.168, 629-638 (2006).(Pubitemid 43271160)
32. Ungvari, Z.et al.Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-?, NAD(P)H oxidase and inducible nitric oxide synthase.Arterioscler.Thromb.Vasc.Biol.23, 418-424 (2003).(Pubitemid 36337217)
33. Towler, D.A., Bidder, M., Latifi, T., Coleman, T.& Semenkovich, C.F.Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice.J.Biol.Chem.273, 30427-30434 (1998).(Pubitemid 28545516)
34. Csiszar, A., Labinskyy, N., Jo, H., Ballabh, P.& Ungvari, Z.Differential proinflammatory and prooxidant effects of bone morphogenetic protein-4 in coronary and pulmonary arterial endothelial cells.Am.J.Physiol. Heart Circ.Physiol.295, H569-H577 (2008).
35. Mathew, S.et al.The mechanism of phosphorus as a cardiovascular risk factor in CKD.J.Am.Soc.Nephrol.19, 1092-1105 (2008).
36. Szymczyk, K.H., Freeman, T.A., Adams, C.S., Srinivas, V.& Steinbeck, M.J.Active caspase-3 is required for osteoclast differentiation.J.Cell.Physiol. 209, 836-844 (2006).(Pubitemid 44665705)
37. Kearns, A.E., Khosla, S.& Kostenuik, P.J.Receptor activator of nuclear factor ?B ligand and osteoprotegerin regulation of bone remodeling in health and disease.Endocr.Rev.29, 155-192 (2008).(Pubitemid 351519689)
38. Sobue, T.et al.Tissue inhibitor of metalloproteinases 1 and 2 directly stimulate the bone-resorbing activity of isolated mature osteoclastS.J.Bone Miner.Res.16, 2205-2214 (2001).(Pubitemid 33104710)
39. Hofbauer, L.C.et al.Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells.Endocrinology 140, 4367-4370 (1999).(Pubitemid 30647136)
40. Sandberg, W.J.et al.Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization.Arterioscler.Thromb. Vasc.Biol.26, 857-863 (2006).(Pubitemid 43732163)
41. Kiechl, S.et al.Soluble receptor activator of nuclear factor-?B ligand and risk for cardiovascular disease.Circulation 116, 385-391 (2007).(Pubitemid 47196543)
42. Shargorodsky, M.et al.Osteoprotegerin as an independent marker of subclinical atherosclerosis in osteoporotic postmenopausal women.Atherosclerosis 204, 608-611 (2009).
43. Kiechl, S.et al.Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease.Circulation 109, 2175-2180 (2004).(Pubitemid 38625393)
44. Browner, W.S., Lui, L.Y.& Cummings, S.R.Association of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures and mortality in elderly women.J.Clin.Endocrinol.Metab.86, 631-637 (2001).(Pubitemid 32207471)
45. Emery, J.G.et al.Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.J.Biol.Chem.273, 14363-14367 (1998).(Pubitemid 28319153)
46. Morony, S.et al.Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in Ldlr(-/-) mice.Circulation 117, 411-420 (2008).
47. Krishnan, V., Bryant, H.U.& MacDougald, O.A.Regulation of bone mass by Wnt signaling.J.Clin.Invest.116, 1202-1209 (2006).
48. Veverka V.et al.Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation.J.Biol.Chem.284, 10890-10900 (2009).
49. Voskaridou E.et al.Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis.Reduction post-zoledronic acid administration.Haematologica 94, 725-728 (2009).
50. Wang F.S.et al.Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss: A histomorphological study in ovariectomized rats.Bone 40, 485-492 (2007).
51. Politou, M.et al.Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation.Int.J.Cancer 119, 1728-1731 (2006).(Pubitemid 44258784)
52. Voorzanger-Rousselot, N.et al.Increased Dickkopf-1 expression in breast cancer bone metastases.Br.J.Cancer 97, 964-970 (2007).(Pubitemid 47519305)
53. Yao, W.et al.Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: A longitudinal study of gene expression in bone tissue from glucocorticoid- treated mice.Arthritis Rheum.58, 1674-1686 (2008).(Pubitemid 351847520)
54. Ohnaka, K., Tanabe, M., Kawate, H., Nawata, H.& Takayanagi, R.Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts.Biochem.Biophys.Res.Commun.329, 177-181 (2005).(Pubitemid 40255437)
55. Jia, D., O'Brien, C.A., Stewart, S.A., Manolagas, S.C.& Weinstein, R.S.Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density.Endocrinology 147, 5592-5599 (2006).(Pubitemid 44833476)
56. Shao, J.S.et al.Msx2 promotes cardiovascular calcification by activating paracrine Wnt signalS.J.Clin.Invest.115, 1210-1220 (2005).
57. Ketteler, M.et al.Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study.Lancet 361, 827-833 (2003).(Pubitemid 36331846)
58. Ix, J.H.et al.Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul Study.Circulation 115, 2533-2539 (2007).(Pubitemid 46763227)
59. Suttamanatwong, S.et al.Sp proteins and Runx2 mediate regulation of matrix Gla protein (MGP) expression by parathyroid hormone.J.Cell.Biochem.107, 284-292 (2009).
60. Eferl, R.et al.The Fos-related antigen Fra-1 is an activator of bone matrix formation.EMBO J.23, 2789-2799 (2004).(Pubitemid 39013551)
61. Jono, S.et al.Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography.Thromb.Haemost. 91, 790-794 (2004).(Pubitemid 38477460)
62. Ueland, T.et al.Undercarboxylated matrix Gla protein is associated with indices of heart failure and mortality in symptomatic aortic stenosiS.J.Intern.Med.268, 483-492 (2010).
63. Schurgers, L.J.et al.The circulating inactive form of matrix Gla protein is a surrogate marker for vascular calcification in chronic kidney disease: A preliminary report.Clin.J.Am.Soc.Nephrol.5, 568-575 (2010).
64. Osako, M.K.et al.Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification.Circ. Res.107, 466-475 (2010).
65. Nofer, J.R.Estrogens and atherosclerosis: insights from animal models and cell systemS.J.Mol.Endocrinol.48, R13-R29 (2012).
66. Sumino, H.et al.Relationship between brachial arterial endothelial function and lumbar spine bone mineral density in postmenopausal women.Circ.J.71, 1555-1559 (2007).(Pubitemid 47529656)
67. Booth, S.L.et al.Vitamin K intake and bone mineral density in women and men.Am.J.Clin.Nutr.77, 512-516 (2003).(Pubitemid 36133397)
68. Hart, J.P.et al.Electrochemical detection of depressed circulating levels of vitamin K1 in osteoporosiS.J.Clin.Endocrinol.Metab.60, 1268-1269 (1985).(Pubitemid 15064795)
69. Hodges, S.J, Akesson, K., Vergnaud, P., Obrant, K.& Delmas, P.D.Circulating levels of vitamins K1 and K2 decreased in elderly women with hip fracture.J.Bone Miner.Res.8, 1241-1245 (1993).(Pubitemid 23308118)
70. Cranenburg, E.C.et al.The circulating inactive form of matrix Gla protein (ucMGP) as a biomarker for cardiovascular calcification.J.Vasc.Res.45, 427-436 (2008).
71. Geleijnse, J.M.et al.Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: The Rotterdam Study.J.Nutr.134, 3100-3105 (2004).(Pubitemid 39470091)
72. Gast, G.C.et al.A high menaquinone intake reduces the incidence of coronary heart disease.Nutr.Metab.Cardiovasc.Dis.19, 504-510 (2009).
73. Shea, M.K.et al.Vitamin K supplementation and progression of coronary artery calcium in older men and women.Am.J.Clin.Nutr.89, 1799-1807 (2009).
74. Bolland, M.J.et al.Vascular events in healthy older women receiving calcium supplementation: randomized controlled trial.BMJ 336, 262-266 (2008).(Pubitemid 351251627)
75. Schurgers, L.J., Aebert, H., Vermeer, C., Bültmann, B.& Janzen, J.Oral anticoagulant treatment: friend or foe in cardiovascular disease? Blood 104, 3231-3232 (2004).(Pubitemid 39507140)
76. Price, P.A., Faus, S.A.& Williamson, M.K.Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves.Arterioscler.Thromb.Vasc.Biol.18, 1400-1407 (1998).(Pubitemid 28421877)
77. Hruska, K.A., Mathew, S., Lund, R., Qiu, P.& Pratt, R.Hyperphosphatemia of chronic kidney disease.Kidney Int.74, 148-157 (2008).(Pubitemid 351915080)
78. Hagström, E.et al.Plasma parathyroid hormone and the risk of cardiovascular mortality in the community.Circulation 119, 2765-2771 (2009).
79. Li, X., Yang, H.Y.& Giachelli, C.M.Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification.Circ.Res.98, 905-912 (2006).
80. Skoumal, M.et al.Serum cathepsin K levels of patients with longstanding rheumatoid arthritis: correlation with radiological destruction.Arthritis Res.Ther.7, R65-R70 (2005).
81. Perez-Castrillon, J.L., Pinacho, F., De Luis, D., Lopez-Menendez, M.& Laita, A.D.Odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women.J.Osteoporos.http://dx.doi.org/10.4061/2010/ 401581.
82. Kitamoto, S.et al.Cathepsin L deficiency reduces diet-induced atherosclerosis in low-density lipoprotein receptor-knockout mice.Circulation 115, 2065-2075 (2007).(Pubitemid 46625958)
83. Lutgens, E.et al.Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation.Circulation 113, 98-107 (2006).(Pubitemid 43958494)
84. Asou, Y.et al.Osteoponotin facilitates angiogenesis, accumulation of osteoclasts, and resorption in ectopic bone.Endocrinology 142, 1325-1332 (2001).(Pubitemid 32202845)
85. Scatena, M., Liaw, L.& Giachelli, C.M.Osteopontin: A multifunctional molecule regulating chronic inflammation and vascular disease.Arterioscler. Thromb.Vasc.Biol.27, 2302-2309 (2007).(Pubitemid 350203943)
86. Speer, M.Y.et al.Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo.J.Exp.Med.196, 1047-1055 (2002).(Pubitemid 35231763)
87. Kadoglou, N.P.et al.The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability.J.Vasc.Surg.47, 55-62 (2008).
88. Wada, T., McKee, M.D., Steitz, S.& Giachelli, C.M.Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin.Circ.Res.84, 166-178 (1999).(Pubitemid 29070112)
89. Suzuki, A., Sekiguchi, S., Asano, S.& Itoh, M.Pharmacological topics of bone metabolism: recent advances in pharmacological management of osteoporosiS.J.Pharmacol.Sci.106, 530-535 (2008).(Pubitemid 351556228)
90. Huang, M.S., Sage, A.P., Lu, J., Demer, L.L.& Tintut, Y.Phosphate and pyrophosphate mediate PKA-induced vascular cell calcification.Biochem.Biophys. Res.Commun.374, 553-558 (2008).
91. Tintut, Y., Patel, J., Parhami, F.& Demer, L.L.Tumor necrosis factor-? promotes in vitro calcification of vascular cells via the cAMP pathway.Circulation 102, 2636-2642 (2000).
92. Tintut, Y., Parhami, F., Boström, K., Jackson, S.M.& Demer, L.L.cAMP stimulates osteoblast-like differentiation of calcifying vascular cells: potential signaling pathway for vascular calcification.J.Biol.Chem.273, 7547-7553 (1998).(Pubitemid 28152780)
93. Mizobuchi, M., Finch, J.L., Martin, D.R.& Slatopolsky, E.Differential effects of vitamin D receptor activators on vascular calcification in uremic rats.Kidney Int.72, 709-715 (2007).(Pubitemid 47373790)
94. Bas, A., Lopez, I., Perez, J., Rodriguez, M.& Aquilera-Tejero, E.Reversibility of calcitriol-induced medial artery calcification in rats with intact renal function.J.Bone Miner.Res.21, 484-490 (2006).
95. Demer, L.L.A skeleton in the atherosclerosis closet.Circulation 92, 2029-2032 (1995).
96. Somjen, D.et al.25-hydroxyvitamin D31?-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds.Circulation 111, 1666-1671 (2005).(Pubitemid 40525167)
97. Parhami, F.et al.Atherogenic high-fat diet reduces bone mineralization in mice.J.Bone Miner.Res.16, 182-188 (2001).(Pubitemid 32046204)
98. Parhami, F., Garfinkel, A.& Demer, L.L.Role of lipids in osteoporosis.Arterioscler.Thromb.Vasc.Biol.20, 2346-2348 (2000).
99. Tintut, Y., Morony, S.& Demer, L.L.Hyperlipidemia promotes osteoclastic potential of bone marrow cells ex vivo.Arterioscler.Thromb.Vasc. Biol.24, 6-10 (2004).
100. Parhami, F.et al.Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation: A possible explanation for the paradox of arterial calcification in osteoporotic patients.Arterioscler. Thromb.Vasc.Biol.17, 680-687 (1997).(Pubitemid 27169128)
101. Yamaguchi, T.et al.Plasma lipids and osteoporosis in postmenopausal women.Endocr.J.49, 211-217 (2002).(Pubitemid 34496340)
102. Mundy, G.et al.Stimulation of bone formation in vitro and in rodents by statins.Science 286, 1946-1949 (1999).(Pubitemid 129515901)
103. Edwards, C.J., Hart, D.J.& Spector, T.D.Oral statins and increased bone-mineral density in postmenopausal women.Lancet 355, 2218-2219 (2000).(Pubitemid 30394332)
104. Meier, C.R., Schlienger, R.G., Kraenzlin, M.E., Schlegel, B.& Jick, H.HMG-CoA reductase inhibitors and the risk of fractures.JAMA 283, 3205-3210 (2000).(Pubitemid 30422037)
105. Shapiro, Y., Boaz, M., Matas, Z., Fux, A.& Shargorodsky, M.The association between the rennin-angiotensin-aldosterone system and arterial stiffness in young healthy subjects.Clin.Endocrinol.(Oxf.) 68, 510-512 (2008).(Pubitemid 351388718)
106. Shimizu, H.et al.Angiotensin II accelerates osteoporosis by activating osteoclasts.FASEB J.22, 2465-2475 (2008).(Pubitemid 351948664)
107. Law, P.H., Sun, Y., Bhattacharya, S.K., Chhokar, V.S.& Weber, K.T.Diuretics and bone loss in rats with aldosteronism.J.Am.Coll.Cardiol.46, 142-146 (2005).(Pubitemid 40905142)
108. Lynn, H., Kwok, T., Wong, S.Y., Woo, J.& Leung, P.C.Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese.Bone 38, 584-588 (2006).
109. Price, P.A., Faus, S.A.& Williamson, M.K.Biphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption.Arterioscler.Thromb.Vasc.Biol.21, 817-824 (2001).(Pubitemid 32448773)
110. Luckman, S.P.et al.Nitrogen-containing biphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including RaS.J.Bone Miner.Res.13, 581-589 (1998).(Pubitemid 28163009)
111. Su, J.Z., Fukuda, N., Kishioka, H., Hu, W.Y.& Kanmatsuse, K.Etidronate influences growth and phenotype of rat vascular smooth muscle cells.Pharmacol.Res.46, 7-13 (2002).(Pubitemid 35300787)
112. Kanazawa, I.et al.Effects of treatment with risedronate and alfacalcidol on progression of atherosclerosis in postmenopausal women with type 2 diabetes mellitus accompanied with osteoporosis.Am.J.Med.Sci.339, 519-524 (2010).
113. Chow, J.T.et al.Abdominal aortic calcification, BMD, and bone microstructure: A population-based study.J.Bone Miner.Res.23, 1601-1612 (2008).
114. Hyder, J.A.et al.Association of coronary artery and aortic calcium with lumbar bone density.The MESA Abdominal Aortic Calcium Study.Am.J.Epidemiol.169, 186-194 (2009).
115. Choi, S.H.et al.Lower bone mineral density is associated with higher coronary calcification and coronary plaque burdens by multidetector row coronary computed tomography in pre-and postmenopausal women.Clin.Endocrinol.71, 644-651 (2009).
116. Hak, A.E., Pols, H.A., van Hemert, A.M., Hofman, A.& Witteman, J.C.Progression of aortic calcification is associated with metacarpal bone loss during menopause: A population-based longitudinal study.Arterioscler.Thromb. Vasc.Biol.20, 1926-1931 (2000).(Pubitemid 30644642)
117. Adragao, T.et al.Low bone volume-a risk factor for coronary calcifications in hemodialysis patients.Clin.J.Am.Soc.Nephrol.4, 350-455 (2009).
118. Tanko, L.B., Bagger, Y.Z.& Christiansen, C.Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women.Calcif.Tissue Int.73, 15-20 (2003).(Pubitemid 37022074)
119. Reddy, J., Bilezikian, J.P., Smith, S.J.& Mosca, L.Reduced bone mineral density is associated with breast arterial calcification.J.Clin. Endocrinol.Metab.93, 208-211 (2008).
120. Uyama, O., Yoshimoto, Y., Yamamoto, Y.& Kawai, A.Bone changes and carotid atherosclerosis in postmenopausal women.Stroke 28, 1730-1732 (1997).(Pubitemid 27391440)
121. Sumino, H.et al.Relationship between carotid atherosclerosis and lumbar spine bone mineral density in postmenopausal women.Hypertens.Res.31, 1191-1197 (2008).
122. Sumino, H.et al.Relationship between brachial arterial endothelial function and lumbar spine bone mineral density in postmenopausal women.Circ.J.71, 1555-1559 (2007).(Pubitemid 47529656)
123. Seo, S.K.et al.Bone mineral density, arterial stiffness and coronary atherosclerosis in healthy postmenopausal women.Menopause 16, 937-943 (2009).
124. Szulc, P., Kiel, D.P.& Delmas, P.D.Calcifications in the abdominal aorta depicts fractures in men: MINOS study.J.Bone Miner.Res.23, 95-102 (2008).
125. Schulz, E., Arfai, K., Liu, X., Sayre, J.& Gilsanz, V.Aortic calcification and the risk of osteoporosis and fractureS.J.Clin.Endocrinol. Metab.89, 4246-4253 (2004).(Pubitemid 39244420)
126. Bagger, Y.Z., Tanko, L.B., Alexandersen, P., Qin, G.& Christiansen, C.Radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip.J.Intern.Med.259, 598-605 (2006).
127. Naves, M., Rodriguez-Garcia, M., Diaz-Lopez, J.B., Gomez-Alonso, C.& Cannata-Andia, J.B.Progression of vascular calcifications is associated with greater bone loss and increased bone fractures.Osteoporos.Int.19, 1161-1166 (2008).
128. Samelson, E.J.et al.Vascular calcification in middle-age and long term risk of hip fracture: the Framingham Study.J.Bone Miner.Res.22, 1449-1454 (2007).(Pubitemid 351339690)
129. Farhat, G.N.et al.The association of bone mineral density measures with incident cardiovascular disease in older adults.Osteoporos.Int.18, 999-1008 (2007).(Pubitemid 46889559)
130. Farhat, G.N.et al.Volumetric and areal bone mineral density measures are associated with cardiovascular disease in older men and women: the health, aging and body composition study.Calcif.Tissue Int.79, 102-111 (2006).(Pubitemid 44306167)
131. Trivedi, D.P.& Khaw, K.T.Bone mineral density at the hip predicts mortality in elderly men.Osteoporos.Int.12, 259-265 (2001).(Pubitemid 34912731)
132. Jorgensen, L., Engstad, T.& Jacobsen, B.Bone mineral density in acute stroke patients, low bone mineral density may predict first stroke in women.Stroke 32, 47-51 (2001).(Pubitemid 32063822)
133. Kiel, D.P.et al.Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study.Calcif.Tissue Int.68, 271-276 (2001).(Pubitemid 32565728)
134. Marcovitz, P.A.et al.Usefulness of bone mineral density to predict significant coronary artery disease.Am.J.Cardiol.96, 1059-1063 (2005).(Pubitemid 41416595)
135. Tanko, L.B.et al.Relationship between osteoporosis and cardiovascular disease in postmenopausal women.J.Bone Miner.Res.20, 1912-1920 (2005).(Pubitemid 41532776)
136. Rodriguez-Garcia, M.et al.Vascular calcifications, vertebral fractures and mortality in haemodiaysis patients.Nephrol.Dial.Transplant.24, 239-246 (2009).
137. Collins, T.C.et al.Peripheral arterial disease is associated with higher rates of hip bone loss and increased fracture risk in older men.Circulation 119, 2305-2312 (2009).
138. Laroche, M.et al.Bone mineral decrease in the leg with unilateral chronic occlusive arterial disease.Clin.Exp.Rheumatol.21, 103-106 (2003).(Pubitemid 36267541)
139. Pennisi, P.et al.Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels.Osteoporos.Int.15, 389-395 (2004).(Pubitemid 38639334)
140. Vogt, M.T., Cauley, J.A., Kuller, L.H.& Nevitt, M.C.Bone mineral density and blood flow to the lower extremities: the study of osteoporotic fractureS.J.Bone Miner.Res.12, 283-289 (1997).(Pubitemid 27086311)
141. Wong, S.Y.et al.Bone mineral density and the risk of peripheral arterial disease in men and women: results from Mr and Ms Os, Hong Kong.Osteoporos.Int. 16, 1933-1938 (2005).(Pubitemid 41790910)
142. van Diepen, S., Majumdar, S.R., Bakal, J.A., McAlister, F.A.& Ezekowitz, J.A.Heart failure is a risk factor for orthopaedic fracture: A population-based analysis of 16,294 patients.Circulation 118, 1946-1952 (2008).
143. Bolland, M.J., Grey, A., Avenell, A., Gamble, G.D.& Reid, I.R.Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis.BMJ 342, d2040 (2011).
144. Hsia, J.et al.Calcium/vitamin D supplementation and cardiovascular events.Circulation 115, 846-854 (2007).(Pubitemid 46294725)
145. Lewis, J.R., Calver, J., Zhu, K., Flicker, L.& Prince, R.L.Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5year RCT and a 4.5year follow-up.J.Bone Miner.Res.26, 35-41 (2011).
146. Wang, T.K.et al.Relationships between vascular calcification, calcium metabolism, bone density, and fractureS.J.Bone Miner.Res.25, 2777-2785 (2010).
147. Bolland, M.J.et al.Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis.BMJ 341, c3691 (2010).
148. Bolland, M.J.et al.Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial.BMJ 336, 262-266 (2008).(Pubitemid 351251627)